Mark Wildgust, The Janssen Pharmaceutical Companies of Johnson and Johnson, shared on LinkedIn:
“Another incredible milestone for our JNJOncology team!.
As this team continues to make strides to advance the science of Lung Cancer, I look forward to what’s to come in the treatment of this disease.”
Read further.
Source: Mark Wildgust/LinkedIn